The combination of anti-IL-1β and anti-PD-1 therapy has shown in preclinical studies to have a synergistic effect that inhibited tumor growth and increased tumor infiltration by cytotoxic CD8+ lymphocytes [41, 42]. The gene discussed is CD8A; the disease is neoplasm.